Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: Tissue processing methodology to optimize pathologic staging and margin assessment - 17/04/15
Abstract |
Background |
Various methods of tissue processing have been used to treat melanoma with Mohs micrographic surgery (MMS).
Objective |
We describe a method of treating melanoma with MMS that combines breadloaf frozen sectioning of the central debulking excision with complete peripheral and deep microscopic margin evaluation, allowing detection of upstaging and comprehensive pathologic margin assessment before reconstruction.
Methods |
We conducted a retrospective cohort study evaluating for local recurrence and upstaging in 614 invasive or in situ melanomas in 577 patients treated with this MMS tissue processing methodology using frozen sections with melanoma antigen recognized by T cells 1 (MART-1) immunostaining. Follow-up was available in 597 melanomas in 563 patients.
Results |
Local recurrence was identified in 0.34% (2/597) lesions with a mean follow-up time of 1026 days (2.8 years). Upstaging occurred in 34 of 614 lesions (5.5%), of which 97% (33/34) were detected by the Mohs surgeon before reconstruction.
Limitations |
Limitations include retrospective study, intermediate follow-up time, and that the recurrence status of 39.6% of patients was self-reported.
Conclusion |
Treating melanoma with MMS that combines breadloaf sectioning of the central debulking excision with complete peripheral and deep microscopic margin evaluation permits identification of upstaging and consideration of sentinel lymph node biopsy before definitive reconstruction and achieves low local recurrence rates compared with conventional excision.
Le texte complet de cet article est disponible en PDF.Key words : immunostaining, melanoma, melanoma antigen recognized by T cells 1, Mohs micrographic surgery, recurrence, upstaging
Abbreviations used : AJCC, MART, MMS, SLNB
Plan
| Funding sources: None. |
|
| Disclosure: Dr Elenitsas serves as a consultant for Myriad Genetics and receives royalties for her work with Lippincott Williams and Wilkins. Drs Etzkorn, Sobanko, Newman, Shin, and Miller, and Ms Goldbach have no conflicts of interest to declare. |
Vol 72 - N° 5
P. 840-850 - mai 2015 Retour au numéro
Article précédent
- Infectious complications in bullous pemphigoid: An analysis of risk factors
- Yee Wei Phoon, Stephanie M.C. Fook-Chong, Hong Yi Koh, Thamotharampillai Thirumoorthy, Shiu Ming Pang, Haur Yueh Lee
- Neurotrophin receptors and perineural invasion in desmoplastic melanoma
- Noah Frydenlund, Dominick A. Leone, Brendon Mitchell, Shi Yang, April Deng, Mai P. Hoang, Meera Mahalingam
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?